Breast Lift in CY
Breast Lift in CY section, includes general infrmation about Breast Lift Procedure, Breast Lift CY Local News, Breast Lift CY Surgeon Locator and other Breast Lift related material.
Breast Lift Procedure
A mastopexy or breast lift is a surgical procedure performed to reshape the breast and return it to a more youthful position. Drooping of the breast may occur after pregnancy as well as aging. Frequently a breast implant may be used in conjunction with a breast lift in order to achieve better results. Depending on the amount of breast lifting that needs to be accomplished, different techniques may be used that involve different incisions. Generally, the more lifting that is required, the larger the incision (and therefore the scar).
Other Breast Lift Procedures
All Breast Procedures
Breast Lift CY (current)
CY Breast Reduction
CY Breast Implants
CY Implant Removal
CY Armpit Incision
More CY info...
Cyprus Get in As Cyprus is a member state of the European Union most travellers from European and North American countries won't need a visa for entry. European Union citizens can enter with a valid identity card, too.
Cyprus By shared taxi Services run every half-hour or so from 6 or 7 in the morning, but terminate at 5 or 6 PM on the dot. You can book a taxi to pick you up anywhere and ask to be dropped off anywhere in city limits; the flip side is that it will often take you longer to get in or out of the city than the journey itself! Figure on £4-6 for a taxi ride on any of these, with an increased price on Sundays and holidays. Also known as a service taxi. Provided only by Travel & Express.
Plastic Surgery News...
- Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) announced that the U.S. Food and Drug Administration (FDA) has accepted for review the submission of the response by Solvay Pharmaceuticals, Inc. to the FDA approvable letter for Once-A-Day LUVOX(R) CR (fluvoxamine maleate) Extended-Release Capsules.
- A retrospective study suggests that antenatal corticosteroid treatment significantly reduces mortality in premature babies of 23 weeks gestation, however the authors caution that overall survival to discharge without adverse events was still very low.
Antenatal corticosteroid treatment is known to reduce respiratory distress and mortality in infants born between 24 and 34 weeks gestation, however it is not clear whether the benefits extend to those born at 23 weeks. As resuscitation at this age is becoming more common, the authors aimed to determine from available records whether they could find evidence of benefit. They carried out a retrospective medical record review across three US tertiary centres to identify infants born at 23 weeks gestation (23 weeks 0 days to 23 weeks 6 days) between the years 1998 and 2007. Pregnancies excluded were those with major foetal malformations, elective terminations, stillbirths, and those where parents declined resuscitation. A multivariable logistic regression model was used to assess the effect of steroids on the odds of death after adjustment for identified confounders. Primary outcome was infant death (death before hospital discharge).
There were 104,614 live births during the study period, and of these, 181 (to 149 mothers) met the inclusion criteria: 63 of the mothers received antenatal corticosteroids - 32 a full course and 31 a part course. Over third of the infants - 66 - died in the delivery room and of the 115 who survived to be admitted to the NNU, only 20 survived to discharge. The main confounding factor was multiple gestations, and after adjustment for this, use of antenatal corticosteroid was associated with a significant decrease in risk of death (odds ratio 0.32; 95% CI 0.12 to 0.84). When the effect of corticosteroid dose was analysed, only exposure to a full course was associated with benefit (OR for death 0.18; 95% CI 0.06 to 0.54). Although numbers of both severe intraventricular bleeding and necrotising enterocolitis were smaller in the corticosteroid group were smaller, the overall numbers affected were too small for any statistically significant difference to be detected.
The authors conclude that in their analysis, infants born at 23 weeks gestation whose mothers had received a complete course of antenatal corticosteroid had an 82% reduction in risk of death. They caution, however, that even amongst those exposed to corticosteroids, only 20% survived to discharge and half of these had severe intraventricular bleeding, necrotising enterocolitis, or both. They hope that their results will prompt randomised controlled trials with longer-term follow-up and economic analysis; nevertheless, they suggest that it would be reasonable to offer a full course of corticosteroid to mothers likely to deliver at 23 weeks, despite the low overall likely survival rate for the baby